-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Tesamorelin 10mg is a synthetic research peptide studied in relation to growth hormone-releasing hormone pathway research, GHRH receptor signalling, GH axis models, IGF-1 pathway research and metabolic pathway studies.
Tesamorelin is commonly described as a synthetic analogue of human growth hormone-releasing hormone, also known as GHRH or growth hormone-releasing factor. PubChem lists Tesamorelin with the molecular formula C221H366N72O67S and molecular weight of approximately 5136 g/mol.
This product is supplied for laboratory research use only. It is not a medicine, supplement, fat loss product, weight loss product, anti-ageing product, muscle growth product, recovery product, hormone therapy product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Tesamorelin |
| Common research names | Tesamorelin, TH9507, GHRH analogue, growth hormone-releasing factor analogue |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Growth Hormone Research / GHRH Analogue Research |
| Common research interest | GHRH receptor signalling, GH axis research, IGF-1 pathway models and metabolic research |
| Peptide type | Synthetic GHRH analogue |
| Approximate molecular formula | C221H366N72O67S |
| Approximate molecular weight | 5136 g/mol |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, weight loss, fat loss, hormone therapy or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Tesamorelin | Synthetic GHRH analogue | Studied in relation to GHRH receptor and GH axis research |
| GHRH analogue structure | Growth hormone-releasing hormone pathway research | Used in endocrine signalling and IGF-1 pathway research models |
| TH9507 | Development or research name | Commonly used in Tesamorelin literature |
| Molecular formula | C221H366N72O67S | Listed by PubChem for Tesamorelin |
| Molecular weight | Approximately 5136 g/mol | Useful for laboratory concentration and molar calculation planning |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Product identity, sequence, salt form, purity, assay result and batch information should always be confirmed through supplier documentation and the Certificate of Analysis. Researchers should not rely on product name alone when confirming peptide identity.
Tesamorelin is studied as a growth hormone-releasing hormone analogue. In research settings, GHRH analogue compounds are examined for how they interact with the GHRH receptor and influence downstream GH axis and IGF-1 pathway models.
Regulated Tesamorelin medicine labels describe EGRIFTA SV as a growth hormone-releasing factor analogue indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, with important limitations including that it is not indicated for weight loss management and that long-term cardiovascular safety has not been established. This regulated medicine context is formulation-specific and must not be used as a product claim for research-use Tesamorelin 10mg vials.
Clinical studies have examined Tesamorelin in specific HIV-associated lipodystrophy contexts, including visceral adipose tissue outcomes, but those controlled clinical findings should not be treated as evidence that a research-use product is approved, safe or effective for human use.
| Research Area | Tesamorelin |
| Main research category | GHRH analogue research |
| Common research name | TH9507 |
| Parent pathway context | Growth hormone-releasing hormone pathway |
| Common receptor interest | GHRH receptor signalling |
| Downstream research interest | GH axis and IGF-1 pathway models |
| Metabolic research interest | Visceral adiposity and endocrine pathway models in controlled research contexts |
| Clinical medicine context | Approved Tesamorelin medicines exist in specific regulated settings overseas |
| Product limitation | Research use only, not approved for human use |
| Feature | Tesamorelin | CJC-1295 No DAC |
| Research class | GHRH analogue research peptide | Modified GRF 1-29 research peptide |
| Main pathway | GHRH receptor pathway | GHRH receptor pathway |
| Common research positioning | GHRH analogue and metabolic pathway research | Shorter GHRH analogue pathway research |
| Common SEO risk | Fat loss, visceral fat and weight loss claims | GH boosting, bodybuilding and anti-ageing claims |
| Safer positioning | GHRH receptor and GH axis research | Modified GRF 1-29 research |
| Human-use claim | Not appropriate for research-use products | Not appropriate for research-use products |
| Feature | Tesamorelin | CJC-1295 with DAC |
| Research class | GHRH analogue research peptide | Long-acting GHRH analogue research peptide |
| Main receptor pathway | GHRH receptor | GHRH receptor |
| Common pathway interest | GH axis, IGF-1 and metabolic research | GH axis and IGF-1 pathway research |
| DAC status | Not positioned as a DAC-containing product | Includes Drug Affinity Complex |
| Common SEO risk | Fat loss and metabolic treatment claims | Anti-ageing, recovery and bodybuilding claims |
| Safer positioning | GHRH analogue research peptide | DAC-containing GHRH analogue research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | Tesamorelin | Ipamorelin |
| Research class | GHRH analogue research peptide | Growth hormone secretagogue research peptide |
| Main pathway | GHRH receptor pathway | Ghrelin receptor / GHSR pathway |
| GH axis position | Upstream GHRH pathway research | Secretagogue pathway research |
| Common research interest | GH axis, IGF-1 and metabolic pathway models | GHSR, ghrelin receptor and endocrine pathway models |
| Common SEO risk | Fat loss and metabolic claims | GH boosting and bodybuilding claims |
| Safer positioning | GHRH receptor pathway research | GHSR pathway research |
| Human-use claim | Not appropriate | Not appropriate |
| Strength | Product Page Positioning |
| Tesamorelin 5mg | Lower-strength research vial for protocol-specific concentration planning |
| Tesamorelin 10mg | Standard research vial for GHRH analogue and GH axis pathway research |
| Tesamorelin 20mg | Higher-strength research vial for larger protocol-specific concentration planning |
Tesamorelin strengths should be treated as product variants, not duplicate product pages. If multiple strengths are listed separately, each page should have a strength-specific title, meta description, slug, concentration table and internal links to reduce SEO cannibalisation.
| Common Online Claim | Safer Research-Use Wording |
| Fat loss | Studied in metabolic and endocrine pathway research models |
| Weight loss | Not an approved or appropriate product claim for research-use material |
| Visceral fat reduction | Only discuss as controlled clinical literature context, not a product-use claim |
| Growth hormone boost | Better framed as GHRH receptor and GH axis pathway research |
| Anti-ageing | Not an approved or appropriate product claim |
| Recovery | Not an approved or appropriate product claim |
| Bodybuilding | Not suitable for research-use product positioning |
| Metabolic treatment | Not appropriate for research-use material |
Tesamorelin 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for weight loss, fat loss, visceral fat reduction, obesity, hormone therapy, muscle growth, recovery, anti-ageing, bodybuilding, performance enhancement, metabolic treatment, general wellness or injection.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Tesamorelin 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, salt form, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
| 20mL | 0.5mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities, treatment quantities or administration schedules.
Before handling Tesamorelin 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Tesamorelin peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps confirm the product is Tesamorelin / TH9507 |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, peptide identity and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible peptide mix-up | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from CJC-1295, Ipamorelin, HGH and AOD-9604 products |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, dose schedules, injection schedules, administration guidance or treatment guidance.
Tesamorelin 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
Regulated Tesamorelin medicines have product-specific prescribing information, formulation-specific administration instructions, sponsor-controlled quality systems and approved indications. Those instructions are not transferable to research-use peptide vials, different strengths, different suppliers or non-approved products.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Peptide identity | Confirmation that the product is Tesamorelin / TH9507 |
| Salt form | Supplier-specific salt form or counter-ion, where documented |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
| Compliance check | Confirmation that no weight loss, fat loss or injection wording is attached to the material |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or regulated medicine information is copied into research-use product content.
Because Tesamorelin is commonly discussed online in relation to visceral fat, body composition and weight loss, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, hormone manipulation, fat loss treatment or metabolic treatment.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide identity | Helps verify the product is Tesamorelin / TH9507 |
| Confirm salt form where documented | Supports correct research calculations |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research pathways from human benefit claims | Avoids unsafe or misleading product positioning |
| Avoid copying regulated medicine instructions | Prevents misleading equivalence with approved products |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a fat loss product | Creates human-use and compliance risk |
| Never make weight loss or visceral fat claims | Not suitable for a research-use product page |
| Never make anti-ageing or recovery claims | Not an approved or appropriate product claim |
| Never imply hormone therapy use | Not suitable for research-use material |
| Never copy dosing from EGRIFTA SV or clinical trial protocols | Formulations, strengths and approved contexts differ |
| Never imply equivalence to approved Tesamorelin medicines | Regulated medicine context is product-specific |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity, treatment quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
| 10mg | 20mL | 0.5mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example, treatment example, injection example or administration instruction.
Tesamorelin is a synthetic GHRH analogue research peptide. It is studied in relation to GHRH receptor signalling, GH axis research, IGF-1 pathway models and endocrine signalling research. PubChem lists Tesamorelin as a synthetic analogue of human growth hormone-releasing hormone.
Yes. Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone. Product identity, sequence and purity should still be confirmed through the Certificate of Analysis before laboratory use.
Tesamorelin is commonly studied in relation to the GHRH receptor pathway, GH axis, IGF-1 pathway models and metabolic research contexts.
EGRIFTA SV is a regulated Tesamorelin medicine indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, but its label also states that it is not indicated for weight loss management. This research-use Tesamorelin 10mg product is not approved or supplied for weight loss, fat loss, obesity, metabolic treatment or human administration.
No. Tesamorelin and CJC-1295 are both discussed in GHRH pathway research, but they are different peptides with different product identities, structures and research positioning.
No. Tesamorelin is usually positioned around GHRH receptor pathway research, while Ipamorelin is usually positioned around ghrelin receptor or GHSR pathway research.
No. Tesamorelin is a GHRH analogue research peptide. HGH, also known as somatropin in regulated medicine contexts, is human growth hormone itself. They are different product classes.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, sequence and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Tesamorelin compound profile | Useful background on Tesamorelin identity, molecular formula and molecular weight. |
| DailyMed EGRIFTA SV Tesamorelin label | Useful regulated medicine context showing product-specific indication, limitations and formulation-specific information. |
Research Use Only: Tesamorelin 10mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use, weight loss, fat loss, visceral fat reduction, obesity treatment, hormone therapy, muscle growth, anti-ageing, recovery, bodybuilding, body enhancement or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation, SDS guidance and qualified laboratory protocols.
